Research library

A

grade

Corticosteroids may reduce the risk of postoperative pancreatic fistula after pancreaticoduodenectomy, but the evidence is not strong enough to recommend their routine use.

Clinically relevant postoperative pancreatic fistula was significantly reduced with corticosteroids (primary analysis: risk difference, -0.09; 95% confidence interval, -0.17 to -0.01; number needed to treat, 11).

summary

B

grade

This case illustrates that recurrent Cushing's disease can arise from tumor cell seeding into the sphenoid sinus during surgery, highlighting the importance of careful surgical techniques.

Not reported in abstract.

summary

B

grade

In treatment-resistant acromegaly, the combination of pasireotide-LAR and pegvisomant may help maintain tumor stability and achieve normal IGF-1 levels, but glucose monitoring is essential due to potential hyperglycemia.

Median follow-up of 3.3 years (range 0.5 to 5.9).

summary

B

grade

The study confirms limited efficacy of somatostatin receptor ligands and dopamine agonists in non-functioning pituitary tumors, with only a small percentage showing any response.

No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).

summary

C

grade

This study confirms limited efficacy of somatostatin and dopamine treatments in non-functioning pituitary tumors, with no strong predictive factors identified for treatment response.

No significant in vitro inhibition of cell proliferation was observed, ranging from -4.2% (OCT and PAS) to -7.4% (BIM-53097 + PAS).

summary

B

grade

A biomarker-guided treatment strategy can lead to hormonal control in nearly 80% of patients with acromegaly, suggesting a shift towards precision medicine in managing this condition.

80% of patients achieved hormonal control with biomarker-guided treatment.

summary

B

grade

Tirzepatide may reduce HbA1c in patients with pasireotide-induced hyperglycemia, but further research is necessary to confirm its effectiveness.

HbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.

summary

B

grade

Tirzepatide may help manage hyperglycemia in patients treated with pasireotide, as evidenced by a decrease in HbA1c from 7.7% to 6.3%. Further research is needed to confirm these findings.

HbA1c decreased from 7.7% to 6.3%.

summary

B

grade

Pasireotide treatment in this infant with congenital hyperinsulinism did not improve glycemic control and may have worsened glycemic variability.

Not reported in abstract.

summary

B

grade

Long-term use of somatostatin analogs may help stabilize patients with occult ectopic ACTH syndrome until surgical intervention can occur.

Not reported in abstract.

summary

A

grade

Switching patients with biochemically controlled acromegaly from injected SRLs to once-daily oral paltusotine was associated with a significant reduction in the frequency of symptom exacerbations.

6.2% (1.6%) of days with symptom exacerbations after switching to paltusotine, n=22, p<0.0001.

summary

A

grade

Paltusotine shows a dose-dependent pharmacokinetic profile and safety in healthy adults, but the small sample size and short duration of the study limit the conclusions about its clinical utility.

Elimination half-life (t_1/2) was 24-28 h.

summary

D

grade

Salivary biomarkers may provide a non-invasive method for assessing endocrine and metabolic disorders, but standardization and validation are crucial for their clinical use.

Not reported in abstract.

summary

A

grade

Pasireotide shows rapid absorption and sustained release in male volunteers with chronic kidney disease and hepatitis B/C, but the clinical implications of these findings are not yet clear.

Maximal concentration at 0.5 h after SC injection(s) of pasireotide (300-900 µg).

summary

D

grade

Pasireotide may restore glucose levels in some insulinoma patients, but its effectiveness varies, especially in aggressive cases.

Seven patients (41%) had complete resolution.

summary

B

grade

GH responsiveness to CRH may help identify a unique subset of tumors in acromegaly, characterized by larger size and reduced hormone secretion capacity.

Not reported in abstract.

summary

B

grade

Pregnancy in women with acromegaly can be managed with careful consideration of treatment strategies, and most pregnancies report favorable fetal outcomes.

Symptom worsening occurred in 16.7-40%.

summary

B

grade

Multi-omics profiling can inform treatment decisions in desmoplastic small round cell tumor, with a 62% disease control rate observed in patients receiving recommended therapies.

62% disease control rate among patients receiving recommended therapies.

summary

C

grade

Dio3 expression is essential for establishing the period of circannual timing in Djungarian hamsters, but findings may not directly apply to humans.

Not reported in abstract.

summary

B

grade

This study highlights a prevalence of acromegaly in Qatar at 1.90 per 100,000, with over half of patients experiencing persistent disease despite surgery.

1.90 per 100,000 (95% CI: 1.41–2.39)

summary

D

grade

Pasireotide and Levoketoconazole can reduce cortisol levels in Cushing’s disease, but the variability in outcomes suggests further research is needed to refine treatment strategies.

Pasireotide showed a mean difference of -331 (95% CI: -1.75e+03, 1.09e+03) in 24-hour urinary free cortisol reduction.

summary

B

grade

ACTH-secreting macroadenomas can lead to severe systemic disease and require lifelong follow-up after treatment.

Not reported in abstract.

summary

B

grade

Pasireotide induces the expression of autophagy-related proteins in cancer cells, but the clinical relevance of these findings is unclear without further studies.

Not reported in abstract.

summary

A

grade

Octreotide and pasireotide may reduce total kidney volume in the short term, while lanreotide may show benefits over a longer period, but the clinical significance of these findings is unclear.

At 6 months or 1 year, octreotide (MD: -3.7, 95%CI: -4.3 to -3.2) and pasireotide (-5.0, -8.2 to -1.8) were associated with TKV reduction compared with placebo.

summary

B

grade

The study suggests that ex vivo drug sensitivity testing in patient-derived cultures may help predict responses to treatments like pasireotide in acromegaly, but findings are based on a small sample.

Median cell viability reduction of 84-86%, p<0.05.

summary